Evidence map›Paper›PMID 34460301›Full record

ArticleAntimicrobial agents and chemotherapy2021

Pharmacokinetics, Tissue Distribution, and Efficacy of VIO-001 (Meropenem/Piperacillin/Tazobactam) for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia in Immunocompetent Rabbits with Chronic Indwelling Vascular Catheters.

Vidmantas Petraitis, Ruta Petraitiene, Povilas Kavaliauskas, Ethan Naing, Andrew Garcia, Christina Sutherland, Aki Yoneda Kau, Nicholas Goldner, Christopher Bulow, David P Nicolau and 1 more

Open access · greenAbstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it

0cells of the map it votes in

6citing papers in PubMed

0.3field-weighted citation impact, top 42% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

An Achilles' heel for methicillin-resistantAntimicrobial agents and chemotherapy · 2026
Review
3,3'-((3-Hydroxyphenyl)azanediyl)dipropionic Acid Derivatives as a Promising Scaffold Against Drug-Resistant Pathogens and Chemotherapy-Resistant Cancer.Pathogens (Basel, Switzerland) · 2025
Article
Synthesis of novel N-substituted β-amino acid derivatives bearing 2-hydroxyphenyl moieties as promising antimicrobial candidates targeting multidrug-resistant Gram-positive pathogens.PloS one · 2025
Article
Exploring the potential of bis(thiazol-5-yl)phenylmethane derivatives as novel candidates against genetically defined multidrug-resistant Staphylococcus aureus.PloS one · 2024
Article
Synthesis of 1-(2-Hydroxyphenyl)- and (3,5-Dichloro-2-hydroxyphenyl)-5-oxopyrrolidine-3-carboxylic Acid Derivatives as Promising Scaffolds for the Development of Novel Antimicrobial and Anticancer Agents.International journal of molecular sciences · 2023
Article
Synthesis and Development ofAntibiotics (Basel, Switzerland) · 2023
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Vidmantas PetraitisTransplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA.ORCID 0000-0001-6811-4467

Ruta PetraitieneTransplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA.ORCID 0000-0002-3269-8058

Povilas KavaliauskasTransplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA.

Ethan NaingTransplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA.

Andrew GarciaTransplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA.

Christina SutherlandCenter for Anti-Infective Research and Development at Hartford Hospitalgrid.277313.3, Hartford, Connecticut, USA.

Aki Yoneda KauViosera Therapeutics, Brentwood, Missouri, USA.

Nicholas GoldnerViosera Therapeutics, Brentwood, Missouri, USA.

Christopher BulowViosera Therapeutics, Brentwood, Missouri, USA.

David P NicolauCenter for Anti-Infective Research and Development at Hartford Hospitalgrid.277313.3, Hartford, Connecticut, USA.ORCID 0000-0002-4148-0165

Thomas J WalshTransplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA.

Cornell University · USHartford Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) infections of surgically implanted subcutaneous vascular catheters (SISVCs) cause serious morbidity in patients with chronic illnesses. Previous

Indexed as

BacteremiaMethicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsVascular Access DevicesAnimalsAnti-Bacterial AgentsMeropenemMicrobial Sensitivity TestsPiperacillin, Tazobactam Drug CombinationRabbitsTissue DistributionAnti-Bacterial AgentsMeropenemPiperacillin, Tazobactam Drug CombinationmeropenemMRSApiperacillinrabbitstazobactamvascular catheter

Identifiers

PMID34460301

DOI10.1128/AAC.01168-21

PMCPMC8522724

OpenAlexW3198003968

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.